v3.24.2.u1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Jul. 31, 2024
Oct. 31, 2023
Current assets:    
Cash and cash equivalents $ 1,225 $ 915
Short-term investments 19,520 22,929
Receivables 410 270
Prepaid expenses and other current assets 1,515 1,242
Total current assets 22,670 25,356
Operating lease right-of-use asset 238 166
Total assets 22,908 25,522
Current liabilities:    
Accounts payable 302 206
Accrued expenses 1,678 1,770
Operating lease liability 24 52
Total current liabilities 2,004 2,028
Operating lease liability, non-current 213 123
Total liabilities 2,217 2,151
Commitments and contingencies (Note 10)
Equity:    
Preferred stock, value
Common stock, par value $.01 per share; 100,000,000 shares authorized; 32,146,460 and 31,145,219 shares issued and outstanding as of July 31, 2024 and October 31, 2023, respectively 321 311
Additional paid-in capital 259,317 252,222
Accumulated deficit (237,867) (228,196)
Total shareholders’ equity 21,771 24,337
Noncontrolling interest (Note 2) (1,080) (966)
Total equity 20,691 23,371
Total liabilities and equity 22,908 25,522
Series A Convertible Preferred Stock [Member]    
Equity:    
Preferred stock, value

Source

PDF HTML
10-Q Filing
ZIP XLS HTML
XBRL
v3.24.2.u1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Jul. 31, 2024
Jul. 31, 2023
Jul. 31, 2024
Jul. 31, 2023
Income Statement [Abstract]        
Revenue $ 210
Operating costs and expenses:        
Inventor royalties, contingent legal fees, litigation and licensing expenses 161
Research and development expenses (including non-cash stock-based compensation expenses of $462, $520, $1,471 and $1,517, respectively) 1,925 1,088 4,920 3,154
General and administrative expenses (including non-cash stock-based compensation expenses of $717, $697, $2,228 and $1,990, respectively) 1,667 1,756 5,748 4,855
Total operating costs and expenses 3,592 2,844 10,668 8,170
Loss from operations (3,592) (2,844) (10,668) (7,960)
Interest income 277 296 883 751
Net loss (3,315) (2,548) (9,785) (7,209)
Less: Net loss attributable to noncontrolling interest (38) (37) (114) (88)
Net loss attributable to common shareholders $ (3,277) $ (2,511) $ (9,671) $ (7,121)
Net loss per common share attributable to common shareholders:        
Basic $ (0.10) $ (0.08) $ (0.30) $ (0.23)
Diluted $ (0.10) $ (0.08) $ (0.30) $ (0.23)
Weighted average common shares outstanding:        
Basic 32,054 30,974 31,804 30,941
Diluted 32,054 30,974 31,804 30,941

Source

PDF HTML
10-Q Filing
ZIP XLS HTML
XBRL
v3.24.2.u1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Jul. 31, 2024
Jul. 31, 2023
Reconciliation of net loss to net cash used in operating activities:    
Net loss $ (9,785) $ (7,209)
Stock option compensation to employees and directors 3,440 3,265
Stock options issued to consultants 101 175
Common stock issued to consultants 255 67
Amortization of operating lease right-of-use asset 28 34
Change in operating assets and liabilities:    
Receivables (140) (288)
Prepaid expenses and other current assets (273) (65)
Accounts payable 96 (171)
Accrued expenses (92) (14)
Operating lease liability (38) (34)
Net cash used in operating activities (6,408) (4,240)
Cash flows from investing activities:    
Disbursements to acquire short-term investments (47,307) (27,502)
Proceeds from maturities of short-term investments 50,716 22,493
Net cash provided by (used in) investing activities 3,409 (5,009)
Cash flows from financing activities:    
Proceeds from sale of common stock in an at-the-market offering, net of offering expenses of $139 2,984
Proceeds from sale of common stock pursuant to an employee stock purchase plan 7 6
Proceeds from exercise of stock options 318 81
Net cash provided by financing activities 3,309 87
Net increase (decrease) in cash and cash equivalents 310 (9,162)
Cash and cash equivalents at beginning of period 915 12,360
Cash and cash equivalents at end of period 1,225 3,198
Supplemental disclosure of non-cash investing activity:    
Operating lease right-of-use asset (100)
Supplemental disclosure of non-cash financing activity:    
Operating lease liability $ 100

Source

PDF HTML
10-Q Filing
ZIP XLS HTML
XBRL